IP Library › Granted Patent US 12,186,436
Granted Patent B2
US 12,186,436 · App. 17/260,640 · Granted Jan 7, 2025

Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents

Inventors: Robert K. Prud'homme (Princeton, NJ); Chester E. Markwalter (Princeton, NJ); Robert F. Pagels (Princeton, NJ)
Assignee: The Trustees of Princeton University
A61K9/5192A61K9/5153A61K9/5169C08G63/08C08G63/664C08G73/1092C08G81/00B82Y5/00B82Y30/00B82Y40/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,186,436
App. No.
17/260,640
Granted
Jan 7, 2025
Kind
B2
Abstract

Hydrophilic molecules such as biologics, which can include peptides, proteins, and other biologically-derived materials, can be used as therapeutic agents in medical applications. They can face administration challenges because of poor membrane permeability and rapid clearance from the blood stream. Methods for the formation of a core-shell-brush nanoparticle from an A-B-C triblock copolymer are set forth. A hydrophilic core can contain the biologic and the C Block of the copolymer. The shell can be comprised of the precipitated B Block, and the A Block can form a stabilizing brush layer. The particles can be assembled by sequential precipitations under defined mixing conditions. Presented herein are methods to tune release based on process parameters during particle assembly and triblock characteristics.

Claims (113)

1. A method for forming a reformed polymer inverse nanoparticle that encapsulates a water soluble active, comprising:

dissolving the water soluble active in an amount of a first process solvent to form a first process solution and dissolving a triblock copolymer in an amount of a second process solvent to form a second process solution;

continuously mixing the first process solution and the second process solution with an amount of a nonprocess solvent to form a first nanoparticle solution comprising a polymer inverse nanoparticle having a core and a shell and a first nanoparticle solvent;

using the first nanoparticle solution as an intermediate solution, adding a second nonprocess solvent to the first nanoparticle solution to form the intermediate solution, or exchanging the first nanoparticle solvent with the second nonprocess solvent to form the intermediate solution; and

continuously mixing the intermediate solution with a reforming solvent to form a reformed nanoparticle solution comprising the reformed polymer inverse nanoparticle having a core and a shell,

wherein the triblock copolymer is a linear [Block A]-[Block B]-[Block C] copolymer,

wherein Block A is selected from the group consisting of poly(ethylene glycol) and poly(propylene oxide),

wherein Block B is hydrophobic and is selected from the group consisting of poly(lactic acid), poly(L-lactide), poly(D-lactide), poly(D,L-lactide), poly(glycolic acid), poly(lactic-co-glycolic acid), poly(caprolactone), poly(hydroxyalkanoate), poly(3-hydroxybutyrate), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate),

wherein Block C is hydrophilic and is selected from the group consisting of poly(aspartic acid) and poly(glutamic acid),

wherein Block A is soluble in the second process solvent, is soluble in the nonprocess solvent, and is soluble in the reforming solvent,

wherein Block B is soluble in the nonprocess solvent and is insoluble in the reforming solvent,

wherein Block C is soluble in the first process solvent, is soluble in the second process solvent, and is insoluble in the nonprocess solvent,

wherein the water soluble active and Block C are in the core of the polymer inverse nanoparticle and are in the core of the reformed polymer inverse nanoparticle,

wherein Block C is not in the shell of the reformed polymer inverse nanoparticle,

wherein Block C does not extend away from the core into the reforming solvent,

wherein the first process solvent is more polar than the nonprocess solvent,

wherein the second process solvent is more polar than the nonprocess solvent,

wherein an intermediate solvent is the intermediate solution without the polymer inverse nanoparticle,

wherein the reforming solvent is more polar than the intermediate solvent,

wherein the amount of the first process solvent, the amount of the second process solvent, and the amount of the nonprocess solvent, when mixed in the absence of the water soluble active or the triblock copolymer, yields a mixture of a single phase or a mixture of which a polar phase is less than 20% of a second phase that is less polar than the polar phase,

wherein the first process solvent is selected from the group consisting of dimethylsulfoxide (DMSO), propanol, ethanol, methanol, water, and a combination,

wherein the second process solvent is selected from the group consisting of dimethylsulfoxide (DMSO), propanol, ethanol, methanol, water, and a combination,

wherein the nonprocess solvent is selected from the group consisting of dichloromethane, chloroform, acetone, tetrahydrofuran (THF), and a combination,

wherein the second nonprocess solvent is selected from dichloromethane, chloroform, acetone, tetrahydrofuran (THF), and a combination,

wherein the reforming solvent is selected from water, methanol, ethanol, propanol, and a combination.

2. The method of claim 1 ,

wherein for the polymer inverse nanoparticle Block B and Block A extend away from the core into the first nanoparticle solvent and

wherein for the reformed polymer inverse nanoparticle Block B is collapsed onto the surface of the core and Block A extends away from the core into the reforming solvent.

3. The method of claim 1 ,

wherein continuously mixing the intermediate solution with the reforming solvent does not induce precipitation of the reformed polymer inverse nanoparticle and wherein the diameter of the reformed polymer inverse nanoparticle is no less than 50% of the diameter of the polymer inverse nanoparticle and is no more than 50% greater than the diameter of the polymer inverse nanoparticle.

4. The method of claim 1 ,

wherein block A has a molecular weight in the range of from 0.2 kDa to 100 kDa, from 0.5 kDa to 50 kDa, from 1 kDa to 20 kDa, from 2 kDa to 10 kDa, or of about 5 kDa,

wherein block B has a molecular weight in the range of from 0.5 kDa to 400 kDa, 1 kDa to 200 kDa, from 2 kDa to 100 kDa, from 5 kDa to 40 kDa, from 10 kDa to 20 kDa, of about 10 kDa, or of about 20 kDa, and

wherein block C has a molecular weight in the range of from 0.2 kDa to 100 kDa, from 0.5 kDa to 50 kDa, from 1 kDa to 20 kDa, from 2 kDa to 10 kDa, or of about 5 kDa.

5. The method of claim 1 ,

wherein block A is poly(ethylene glycol),

wherein block B is selected from the group consisting of poly(lactic acid), poly(lactic-co-glycolic acid), and poly(caprolactone), and

wherein block C is selected from the group consisting of poly(aspartic acid) and poly(glutamic acid).

6. The method of claim 1 ,

wherein block A has a molecular weight in the range of from 1 kDa to 10 kDa, from 2 kDa to 8 kDa, or of about 5 kDa,

wherein block B has a molecular weight in the range of from 2 kDa to 100 kDa, 5 kDa to 50 kDa, from 10 kDa to 20 kDa, of about 10 kDa, or of about 20 kDa, and

wherein block C has a molecular weight in the range of from 1 kDa to 10 kDa, from 2 kDa to 8 kDa, or of about 5 kDa.

7. The method of claim 1 ,

wherein block A is poly(ethylene glycol) (PEG),

wherein block B is poly(lactic acid) (PLA), and

wherein block C is poly(aspartic acid) (PAsp).

8. The method of claim 7 ,

wherein block A has a molecular weight in the range of from 1 kDa to 10 kDa, from 2 kDa to 8 kDa, or of about 5 kDa,

wherein block B has a molecular weight in the range of from 2 kDa to 100 kDa, 5 kDa to 50 kDa, from 10 kDa to 20 kDa, of about 10 kDa, or of about 20 kDa, and

wherein block C has a molecular weight in the range of from 1 kDa to 10 kDa, from 2 kDa to 8 kDa, or of about 5 kDa.

9. The method of claim 1 , wherein the polymer inverse nanoparticle has the core comprising the water soluble active and block C and has the shell comprising block A and block B.

10. The method of claim 1 , wherein the reformed polymer inverse nanoparticle has the core comprising the water soluble active, block B, and block C and has the shell comprising block A.

11. The method of claim 1 , further comprising dissolving a lipid in the first process solution or the second process solution.

12. The method of claim 1 ,

wherein the first process solvent and the second process solvent are the same solvent and together are a single process solvent,

wherein the water soluble active and the triblock copolymer are dissolved in the single process solvent to form a single process solution,

wherein the single process solution represents the first process solution and the second process solution, and

wherein the single process solution is continuously mixed with the amount of the nonprocess solvent to form the first nanoparticle solution comprising a polymer inverse nanoparticle having a core and a shell and a first nanoparticle solvent.

13. The method of claim 12 ,

wherein the second nonprocess solvent is the same solvent as the single process solvent.

14. The method of claim 1 ,

wherein the first nanoparticle solvent is exchanged with the second nonprocess solvent to form the intermediate solution and

wherein the first nanoparticle solvent is not miscible with the reforming solvent.

15. The method of claim 1 ,

wherein the first process solvent is selected from the group consisting of dimethylsulfoxide (DMSO), propanol, ethanol, methanol, water, and combinations,

wherein the second process solvent is selected from the group consisting of dimethylsulfoxide (DMSO), propanol, ethanol, methanol, water, and combinations,

wherein the nonprocess solvent is selected from the group consisting of dichloromethane, chloroform, acetone, and tetrahydrofuran (THF),

wherein the second nonprocess solvent is selected from the group consisting of dichloromethane, chloroform, acetone, and tetrahydrofuran (THF), and

wherein the reforming solvent is selected from the group consisting of water, methanol, ethanol, and propanol.

16. The method of claim 1 , wherein the water soluble active is selected from the group consisting of a linear polypeptide and a cyclic polypeptide.

17. The method of claim 1 , wherein the first process solvent is completely miscible with the nonprocess solvent and wherein the second process solvent is completely miscible with the nonprocess solvent.

18. The method of claim 1 , wherein the continuous mixing is through a flash nanoprecipitation process.

19. The method of claim 1 , further comprising crosslinking block C.

20. The method of claim 1 , further comprising ionically crosslinking block C with an organic compound.

21. The method of claim 1 , further comprising removing the nonprocess solvent from the reformed nanoparticle solution.

22. The method of claim 1 , further comprising

identifying the desired rate of release of the water soluble active from the reformed polymer inverse nanoparticle and

continuously mixing the intermediate solution with the reforming solvent at a temperature in the range of from 1° C. to 10° C., in the range of from 4° C. to 8° C., or at about 5° C. to achieve a fast rate of release, or

continuously mixing the intermediate solution with the reforming solvent at a temperature in the range of from 15° C. to 35° C., in the range of from 17° C. to 30° C., in the range of from 20° C. to 25° C., or at about 20° C. to achieve a slow rate of release.

23. The method of claim 12 ,

wherein the triblock copolymer is poly(ethylene glycol)-poly(lactic acid)-poly(aspartic acid),

wherein the water soluble active is a polypeptide,

wherein the single process solvent is DMSO or a solution of DMSO and water,

wherein the nonprocess solvent is dichloromethane or chloroform,

wherein following formation of the first nanoparticle solution, the poly(aspartic acid) block is crosslinked through addition of tetraethylene pentamine,

wherein the first nanoparticle solvent is exchanged with the second nonprocess solvent to form the intermediate solution, and

wherein the second nonprocess solvent is acetone.

24. The method of claim 1 , wherein the reforming solvent is water.

25. The method of claim 1 , wherein the reforming solvent is methanol.

26. The method of claim 12 ,

wherein the triblock copolymer is poly(ethylene glycol)-poly(lactic acid)-poly(aspartic acid),

wherein the water soluble active is a polypeptide,

wherein the single process solvent comprises DMSO or a solution of DMSO and water,

wherein the nonprocess solvent is acetone,

wherein following formation of the first nanoparticle solution, the poly(aspartic acid) block is crosslinked through addition of tetraethylene pentamine,

wherein the second nonprocess solvent is added to the first nanoparticle solution,

wherein the second nonprocess solvent is acetone, and

wherein the reforming solvent is water.

27. The method of claim 12 ,

wherein a lipid is dissolved into the single process solution and

wherein the single process solvent comprises DMSO, ethanol, and water.

28. The method of claim 1 ,

wherein the triblock copolymer is poly(ethylene glycol)-poly(lactic acid)-poly(aspartic acid),

wherein the water soluble active is a polypeptide,

wherein the first process solvent is a solution of DMSO and water,

wherein the second process solvent is DMSO,

wherein the nonprocess solvent is a solution of tetrahydrofuran (THF) and chloroform,

wherein following formation of the first nanoparticle solution, the poly(aspartic acid) block is crosslinked,

wherein the first nanoparticle solvent is exchanged with the second nonprocess solvent to form the intermediate solution,

wherein the second nonprocess solvent is acetone, and

wherein the reforming solvent is water.

29. The method of claim 1 , wherein Block A is poly(propylene oxide).

30. The method of claim 1 , wherein Block B is poly(3-hydroxybutyrate-co-3-hydroxyvalerate).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2021
From: PRUD'HOMME, ROBERT K.; MARKWALTER, CHESTER E.; PAGELS, ROBERT F.
To: THE TRUSTEES OF PRINCETON UNIVERSITY
Reel/Frame 054985/0225 →
Continuity (2)
Provisional Application 62700854 · Jul 19, 2018
Related Publication 20210259984A1 · Aug 26, 2021
References Cited (341)
US 1690760A · Volwiler · 1928 [cited by applicant]
US 4342653A · Halverson · 1982 [cited by applicant]
US 4382982A · Whillans · 1983 [cited by applicant]
US 4678516A · Alderman · 1987 [cited by applicant]
US 4695464A · Alderman · 1987 [cited by applicant]
US 4888238A · Katz et al. · 1989 [cited by applicant]
US 4999417A · Domb · 1991 [cited by applicant]
US 5366734A · Hutchinson · 1994 [cited by applicant]
US 5578325A · Domb et al. · 1996 [cited by applicant]
US 5851579A · Wu · 1998 [cited by applicant]
US 6291013B1 · Gibson · 2001 [cited by applicant]
US 6383500B1 · Wooley et al. · 2002 [cited by applicant]
US 6610653B1 · Backstrom et al. · 2003 [cited by applicant]
US 6730322B1 · Bernstein et al. · 2004 [cited by applicant]
US 6998426B2 · L'Alloret · 2006 [cited by applicant]
US 7052719B2 · Bernstein · 2006 [cited by applicant]
US 7842308B2 · McAllister et al. · 2010 [cited by applicant]
US 7977024B2 · Zhou et al. · 2011 [cited by applicant]
US 8137699B2 · Johnson · 2012 [cited by applicant]
US 8288001B1 · Fan et al. · 2012 [cited by applicant]
US 8298581B2 · Fischer et al. · 2012 [cited by applicant]
US 8603514B2 · Yang · 2013 [cited by applicant]
US 8623329B1 · Hansen et al. · 2014 [cited by applicant]
US 8703196B2 · Babcock et al. · 2014 [cited by applicant]
US 9504658B2 · Miller et al. · 2016 [cited by applicant]
US 9603830B2 · Llc · 2017 [cited by applicant]
US 9782358B2 · Kataoka et al. · 2017 [cited by applicant]
US 10231937B2 · Pagels et al. · 2019 [cited by applicant]
US 11103461B2 · Prud'Homme et al. · 2021 [cited by applicant]
US 20040023393A1 · Monahan et al. · 2004 [cited by applicant]
US 20040052824A1 · Chacra-Vernet · 2004 [cited by applicant]
US 20040091546A1 · Johnson et al. · 2004 [cited by applicant]
US 20040236050A1 · Lundquist et al. · 2004 [cited by applicant]
US 20050158390A1 · Rana et al. · 2005 [cited by applicant]
US 20050228074A1 · Warren et al. · 2005 [cited by applicant]
US 20060040831A1 · Cassidy et al. · 2006 [cited by applicant]
US 20060057215A1 · Raiche et al. · 2006 [cited by applicant]
US 20060078624A1 · Zalipsky et al. · 2006 [cited by applicant]
US 20060159921A1 · Murthy et al. · 2006 [cited by applicant]
US 20060224095A1 · Claverie · 2006 [cited by examiner]
US 20060247383A1 · Hedrick et al. · 2006 [cited by applicant]
US 20070042498A1 · Ebner · 2007 [cited by applicant]
US 20070231355A1 · Quadir et al. · 2007 [cited by applicant]
US 20080145432A1 · Kakizawa et al. · 2008 [cited by applicant]
US 20080160305A1 · Warren et al. · 2008 [cited by applicant]
US 20080274194A1 · Miller et al. · 2008 [cited by applicant]
US 20090061009A1 · Schwarz et al. · 2009 [cited by applicant]
US 20090068743A1 · Turnell et al. · 2009 [cited by applicant]
US 20090155326A1 · Mack et al. · 2009 [cited by applicant]
US 20090325292A1 · Baker et al. · 2009 [cited by applicant]
US 20100150994A1 · Kotyla · 2010 [cited by applicant]
US 20100166866A1 · Fischer et al. · 2010 [cited by applicant]
US 20100203149A1 · Radosz et al. · 2010 [cited by applicant]
US 20100233251A1 · Von Andrian et al. · 2010 [cited by applicant]
US 20100305219A1 · Granick et al. · 2010 [cited by applicant]
US 20100310649A1 · Richard et al. · 2010 [cited by applicant]
US 20100330368A1 · Prud'homme et al. · 2010 [cited by applicant]
US 20110012057A1 · Lindner et al. · 2011 [cited by applicant]
US 20110022129A1 · Prud'homme et al. · 2011 [cited by applicant]
US 20110064821A1 · Catchpole et al. · 2011 [cited by applicant]
US 20110200828A1 · Li et al. · 2011 [cited by applicant]
US 20110206739A1 · Nicolosi et al. · 2011 [cited by applicant]
US 20110229516A1 · Ochomogo et al. · 2011 [cited by applicant]
US 20110236686A1 · Kitano et al. · 2011 [cited by applicant]
US 20110293701A1 · Bratzler et al. · 2011 [cited by applicant]
US 20120009267A1 · Cho et al. · 2012 [cited by applicant]
US 20120041150A1 · Yabu et al. · 2012 [cited by applicant]
US 20120121510A1 · Brem et al. · 2012 [cited by applicant]
US 20120171254A1 · Johnson et al. · 2012 [cited by applicant]
US 20120230913A1 · Johnston et al. · 2012 [cited by applicant]
US 20120308640A1 · Percec et al. · 2012 [cited by applicant]
US 20130064954A1 · Ochomogo et al. · 2013 [cited by applicant]
US 20130101516A1 · Zhao · 2013 [cited by applicant]
US 20130115272A1 · Therapeutics · 2013 [cited by applicant]
US 20130122058A1 · Chow et al. · 2013 [cited by applicant]
US 20130171208A1 · Smith et al. · 2013 [cited by applicant]
US 20130337078A1 · Mayer et al. · 2013 [cited by applicant]
US 20140037573A1 · Eliasof et al. · 2014 [cited by applicant]
US 20140099379A1 · Beck-Broichsitter et al. · 2014 [cited by applicant]
US 20140249235A1 · Brugel et al. · 2014 [cited by applicant]
US 20140302154A1 · Ag · 2014 [cited by applicant]
US 20140356443A1 · Brisander et al. · 2014 [cited by applicant]
US 20150086618A1 · Onyuksel et al. · 2015 [cited by applicant]
US 20150218198A1 · Petermann et al. · 2015 [cited by applicant]
US 20150283218A1 · Shea et al. · 2015 [cited by applicant]
US 20150290233A1 · Ltd. · 2015 [cited by applicant]
US 20150298084A1 · Schoeppe et al. · 2015 [cited by applicant]
US 20150299369A1 · Ausserre et al. · 2015 [cited by applicant]
US 20160235677A1 · Hoerr et al. · 2016 [cited by applicant]
US 20160317459A1 · Ensign et al. · 2016 [cited by applicant]
US 20160346266A1 · Tolleth et al. · 2016 [cited by applicant]
US 20170042823A1 · Prud'Homme et al. · 2017 [cited by applicant]
US 20170151339A1 · White et al. · 2017 [cited by applicant]
US 20170209386A1 · Pagels et al. · 2017 [cited by applicant]
US 20180009924A1 · Sadowski et al. · 2018 [cited by applicant]
US 20180125915A1 · Mikhail · 2018 [cited by applicant]
US 20190008788A1 · Prud'Homme et al. · 2019 [cited by applicant]
US 20190151252A1 · Pagels et al. · 2019 [cited by applicant]
US 20190192444A1 · Barzilay et al. · 2019 [cited by applicant]
US 20200023332A1 · Prud'homme et al. · 2020 [cited by applicant]
US 20200147032A1 · Prud'homme et al. · 2020 [cited by applicant]
US 20200206136A1 · Prud'homme et al. · 2020 [cited by applicant]
US 20210085619A1 · Baldwin et al. · 2021 [cited by applicant]
US 20210378980A1 · Horhota et al. · 2021 [cited by applicant]
US 20210379181A1 · Rauch et al. · 2021 [cited by applicant]
CN 100389766C · 2008 [cited by applicant]
CN 102334609A · 2012 [cited by applicant]
CN 104042567A · 2014 [cited by applicant]
CN 105213250A · 2016 [cited by applicant]
CN 106750272A · 2017 [cited by applicant]
EP 2962752A1 · 2016 [cited by applicant]
JP 2000514791A · 2000 [cited by applicant]
JP 2003513019A · 2003 [cited by applicant]
JP 2008297288A · 2008 [cited by applicant]
JP 2011506499A · 2011 [cited by applicant]
JP 2014514275A · 2014 [cited by applicant]
JP 2015129128A · 2015 [cited by applicant]
JP 2015529683A · 2015 [cited by applicant]
JP 2017505800A · 2017 [cited by applicant]
JP 2018535228A · 2018 [cited by applicant]
WO WO1994008599A1 · 1994 [cited by applicant]
WO WO1997049387A1 · 1997 [cited by applicant]
WO WO1997049736A2 · 1997 [cited by applicant]
WO WO2001022937A1 · 2001 [cited by applicant]
WO WO2002076441A1 · 2002 [cited by applicant]
WO WO2002078674A1 · 2002 [cited by applicant]
WO WO2002092069A1 · 2002 [cited by applicant]
WO WO2009080164A1 · 2009 [cited by applicant]
WO WO2010148653A1 · 2010 [cited by applicant]
WO WO2012122544A2 · 2012 [cited by applicant]
WO WO2013023003A1 · 2013 [cited by applicant]
WO WO2013160773A2 · 2013 [cited by applicant]
WO WO2014043625A1 · 2014 [cited by applicant]
WO WO2014133172A1 · 2014 [cited by applicant]
WO WO2014165679A1 · 2014 [cited by applicant]
WO WO2015123562A1 · 2015 [cited by applicant]
WO WO2015130835A1 · 2015 [cited by applicant]
WO WO2015200054A2 · 2015 [cited by examiner]
WO WO2015200054A9 · 2015 [cited by applicant]
WO WO2016193810A1 · 2016 [cited by applicant]
WO WO2017089942A1 · 2017 [cited by applicant]
WO WO2017112828A1 · 2017 [cited by applicant]
WO WO2017130046A1 · 2017 [cited by applicant]
WO WO2019050969A1 · 2019 [cited by applicant]
WO WO2019055539A1 · 2019 [cited by applicant]
WO WO2019090030A1 · 2019 [cited by applicant]
WO WO2020018890A1 · 2020 [cited by applicant]
WO WO2020227350A1 · 2020 [cited by applicant]
WO WO2020252346A1 · 2020 [cited by applicant]
WO WO2021046078A1 · 2021 [cited by applicant]
Kader A. and Jalil R. In Vitro Release of Theophylline from Poly(Lactic Acid) Sustained-Release Pellets. Prepared by Direct Compression. Drug Development and Industrial Pharmacy, 24(6), 527-534 (1998) (Year: 1998). [cited by examiner]
Lan Q et al. Preparation and Characterization of Super Cross-Linked Poly(ethylene oxide) Gel Polymer Electrolyte for Lithium-Ion Battery . Science of Advanced Materials, vol. 9, No. 6, Jun. 2017, pp. 988-994(7) (Year: 2… [cited by examiner]
International Patent Application PCT/US2018/050714 International Search Report and Written Opinion dated Dec. 6, 2018. [cited by applicant]
International Patent Application PCT/US2018/058869 International Search Report and Written Opinion dated Feb. 22, 2019. [cited by applicant]
International Patent Application PCT/US2019/042574 International Search Report and Written Opinion dated Nov. 22, 2019. [cited by applicant]
International Patent Application PCT/US2020/031579 International Search Report and Written Opinion dated Aug. 3, 2020. [cited by applicant]
International Patent Application PCT/US2020/037542 International Search Report and Written Opinion dated Sep. 11, 2020. [cited by applicant]
International Patent Application PCT/US2020/048986 International Search Report and Written Opinion dated Feb. 16, 2021. [cited by applicant]
IQQueryQuickExport search results—202004301516 (IP.com NPL search results)—downloaded Apr. 30, 2020, 4 pages. [cited by applicant]
IQQueryQuickExport search results—202004301547 (IP.com NPL search results)—downloaded Apr. 30, 2020, 2 pages. [cited by applicant]
IQQueryQuickExport search results—202004301605 (IP.com NPL search results)—downloaded Apr. 30, 2020, 5 pages. [cited by applicant]
IQQueryQuickExport search results—202004301643 (IP.com NPL search results)—downloaded Apr. 30, 2020, 5 pages. [cited by applicant]
IQQueryQuickExport search results—202004301659 (IP.com NPL search results)—downloaded Apr. 30, 2020, 5 pages. [cited by applicant]
IQQueryQuickExport search results—202004301700 (IP.com NPL search results)—downloaded Apr. 30, 2020, 2 pages. [cited by applicant]
Jain et al., “Peptide and Protein Delivery Using New Drug Delivery Systems”, Crit. Revs. Ther. Drug Carrier Syst., vol. 30, No. 4, pp. 293-329 (2013). [cited by applicant]
Jang et al., “Bicontinuous Block Copolymer Morphologies Produced by Interfacially Active, Thermally Stable Nanoparticles”, Macromols., vol. 44, pp. 9366-9373 (2011). [cited by applicant]
Jang et al., “Synthesis of thermally stable Au-core/Pt-shell nanoparticles and their segregation behavior in diblock copolymer mixtures”, Soft Matter, vol. 7, pp. 6255-6263 (2011), doi: 10.1039/clsm05223c. [cited by applicant]
Jeon et al., “Cooperative Assembly of Block Copolymers with Deformable Interfaces: Toward Nanostructured Particles”, Advanced Materials, vol. 20, pp. 4103-4108 (2008), doi: 10.1002/adma.200801377. [cited by applicant]
Johnson et al., “Characterization and Suitability of Therapeutic Antibody Dense Phases for Subcutaneous Delivery”, Molecular Pharmaceutics, vol. 10, pp. 3582-3591 (2013). [cited by applicant]
Johnson et al., “Chemical Processing and Micromixing in Confined Impinging Jets”, AlChE Journal, vol. 49, No. 9, pp. 2264-2282 (2003). [cited by applicant]
Johnson et al., “Flash NanoPrecipitation of Organic Actives and Block Copolymers using a Confined Impinging Jets Mixer,” Australian Journal of Chemistry, vol. 56, No. 10, pp. 1021-1024 (2003). [cited by applicant]
Johnson et al., “Nanoprecipitation of Organic Actives Using Mixing and Block Copolymer Stabilization”, Abstracts of Papers of the American Chemical Society, No. 186 (Abstract) (Sep. 2003). [cited by applicant]
Johnson et al., “Engineering the Direct Precipitation of Stabilized Organic and Block Copolymer Nonparticles as Unique Composites”, Abstracts of Papers of the American Chemical Society, No. 441 (Abstract) (Sep. 2003). [cited by applicant]
Johnston et al., “Concentrated Dispersions of Equilibrium Protein Nanoclusters That Reversibly Dissociate into Active Monomers”, ACS Nano, vol. 6, No. 2, pp. 1357-1369 (2012). [cited by applicant]
Kakizawa et al., “Controlled release of protein drugs from newly developed amphiphilic polymer-based microparticles composed of nanoparticles”, Journal of Controlled Release, vol. 142, pp. 8-13 (2010). [cited by applicant]
Kang et al., “Pore Closing and Opening in Biodegradable Polymers and Their Effect on the Controlled Release of Proteins”, Mol. Pharmaceutics, vol. 4, No. 1, pp. 104-118 (2007). [cited by applicant]
Khanvilkar et al., “Drug transfer through mucus,” Advanced Drug Delivery Reviews, vol. 48, Nos. 2-3, pp. 173-193 (2001). [cited by applicant]
Kim et al., “Critical effect of freezing/freeze-drying on sustained release of FITC-dextran encapsulated within PLGA rnicrospheres”, Int'l J. Pharmaceutics, vol. 271, pp. 207-214 (2004). [cited by applicant]
Kim et al., “Multicomponent Nanoparticles via Self-Assembly with Cross-Linked Block Copolymer Surfactants”, Langmuir, vol. 23, pp. 2198-2202 (2007). [cited by applicant]
Kohen, N., “Characterization of Polystyrene-block-poly(acrylic acid) Micelles In Solution and Assembled on Solid Substrates”, Massachusetts Institute of Technology, Thesis, pp. 1-38 (Jun. 2005). [cited by applicant]
Kovalainen et al., “Novel Delivery Systems for Improving the Clinical Use of Peptides”, Pharmacol. Rev., vol. 67, No. 3, pp. 541-561 (Jul. 2015). [cited by applicant]
Kumar et al., “Amphiphilic Janus particles at fluid interfaces”, Soft Matter, vol. 9, pp. 6604-6617 (2013). [cited by applicant]
Lai et al., “Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues,” Advanced Drug Delivery Reviews, vol. 61, No. 2, pp. 158-171 (2009). [cited by applicant]
Lai et al., “Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus,” Proceedings National Academy of Sciences, vol. 104, No. 5, pp. 1482-1487 (Jan. 30, 2007). [cited by applicant]
Langer, R., “Drug delivery and targeting”, Nature, vol. 392, No. 6679, pp. 5-10 (Apr. 30, 1998). [cited by applicant]
Lavasanifar et al., “Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery”, Advanced Drug Delivery Reviews, vol. 54, pp. 169-190 (2002). [cited by applicant]
Li et al., “Pharmacokinetics and Biodistribution of Nanoparticles”, Molecular Pharmaceutics, vol. 5, No. 4, pp. 496-504 (2008). [cited by applicant]
Liang et al., “Preparation of nanoparticles composed of poly(gamma-glutamic acid)-poly(lactide) block copolymers and evaluation of their uptake by HepG2 cells”, J. Controlled Release, vol. 105, pp. 213-225 (2005). [cited by applicant]
Liu et al., CFD Predictions for Chemical Processing in a Confined Impinging-Jets Reactor', AlChE Journal, vol. 52, No. 2, pp. 731-744 (Feb. 2006). [cited by applicant]
Liu et al., “Janus Colloids Formed by Biphasic Grafting at a Pickering Emulsion Interface”, Angew. Chem., vol. 120, pp. 4037-4039 (2008). [cited by applicant]
Liu, Y et al., “Mixing in a multi-inlet vortex mixer (MIVM) for flash nano-precipitation”, Chemical Engineering Science, (2008), vol. 63, No. 11, pp. 2829-2842. [cited by applicant]
Liu et al., “Ostwald Ripening of beta-Carotene Nanoparticles”, Phys. Rev. Lett., vol. 98, No. 3, p. 036102-1 - 036102-4 (2007). [cited by applicant]
Livraghi et al., “Cystic Fibrosis and Other Respiratory Diseases of Impaired Mucus Clearance”, Toxicologic Pathology, vol. 35, No. 1, pp. 116-129 (2007). [cited by applicant]
Lu et al., “Hydrophobic lon Pairing of Peptide Antibiotics for Processing into Controlled Release Nanocarrier Formulations”, Molecular Pharmaceutics, vol. 15, No. 1, pp. 216-225 (2018). [cited by applicant]
Luo et al., “Synthetic DNA delivery systems,” Nature Biotechnology, vol. 18, No. 1, pp. 33-37 (Jan. 2000). [cited by applicant]
Mai et al., “Controlled Incorporation of Particles into the Central Portion of Vesicle Walls”, J. Am. Chem. Soc., vol. 132, p. 10078-10084 (2010). [cited by applicant]
Marcus et al., “Ion Pairing”, Chemical Reviews, vol. 106, No. 11, pp. 4585-4621 (2006). [cited by applicant]
Markwalter et al., “Inverse Flash NanoPrecipitation for Biologics Encapsulation: Understanding Process Losses via an Extraction Protocol”, Control of Amphiphile Self-Assembling at the Molecular Level: Supra-Molecular As… [cited by applicant]
Matschiner et al., “Optimization of Topical Erythromycin Formulations by lon Pairing”, Skin Pharmacology: The Official Journal of the Skin Pharmacology Society, vol. 8, No. 6, pp. 319-325 (1995). [cited by applicant]
Meyer et al., “Hydrophobic lon Pairing: Altering the Solubility Properties of Biomolecules”, Pharmaceutical Research, vol. 15, No. 2, pp. 188-193 (1998). [cited by applicant]
Mitragotri et al., “Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies”, Nat. Rev. Drug Discov., vol. 13, No. 9, pp. 655-672 (41 pages) (Sep. 2014). [cited by applicant]
Muehle et al., “Stability of Particle Aggregates in Flocculation with Polymers: Stabilitaet vonder Flockung mit Polymeren”, Chemical Engineering & Processing: Process Intensification,(1991). [cited by applicant]
U.S. Appl. No. 16/253,850 U.S. Patent & Trademark Office (USPTO) Communication dated Mar. 9, 2021. [cited by applicant]
U.S. Appl. No. 16/253,850 Notice of Allowance & Notice of Allowability dated Apr. 12, 2022. [cited by applicant]
U.S. Appl. No. 16/253,850, filed Aug. 11, 2021 dated Summary of Interview of Aug. 9, 2021. [cited by applicant]
U.S. Appl. No. 16/253,850 Office Action dated Sep. 23, 2021. [cited by applicant]
U.S. Appl. No. 16/253,850 Notice of Allowance & Notice of Allowability dated Sep. 13, 2022. [cited by applicant]
U.S. Appl. No. 16/253,850 Supplemental Notice of Allowability dated Dec. 19, 2022. [cited by applicant]
U.S. Appl. No. 16/517,510 Restriction/Election Requirement dated Mar. 19, 2021. [cited by applicant]
U.S. Appl. No. 16/517,510 Office Action dated Sep. 24, 2021. [cited by applicant]
U.S. Appl. No. 16/517,510 Notice of Allowance & Notice of Allowability dated May 9, 2022. [cited by applicant]
U.S. Appl. No. 16/517,510 Notice of Allowance & Notice of Allowability dated Nov. 23, 2022. [cited by applicant]
U.S. Appl. No. 16/517,510 Notice of Allowance & Notice of Allowability dated Apr. 19, 2023. [cited by applicant]
U.S. Appl. No. 16/761,140 Office Action dated Feb. 14, 2024. [cited by applicant]
U.S. Appl. No. 16/761,140 Office Action dated Jun. 5, 2023. [cited by applicant]
U.S. Appl. No. 16/761,140 Office Action dated Feb. 8, 2022. [cited by applicant]
U.S. Appl. No. 16/761,140 Office Action dated Aug. 26, 2022. [cited by applicant]
U.S. Patent Application 16/761, 140 Restriction/Election Requirement dated Aug. 19, 2021. [cited by applicant]
U.S. Appl. No. 16/816,241 Office Action dated May 12, 2022. [cited by applicant]
U.S. Appl. No. 16/816,241 Restriction/Election Requirement dated Sep. 30, 2021. [cited by applicant]
U.S. Appl. No. 16/816,241 Notice of Allowance & Notice of Allowability dated Nov. 16, 2022. [cited by applicant]
U.S. Appl. No. 16/816,241 Notice of Allowance & Notice of Allowability dated Mar. 7, 2023. [cited by applicant]
U.S. Appl. No. 16/816,241 Notice of Allowance & Notice of Allowability dated Apr. 13, 2023. [cited by applicant]
U.S. Appl. No. 16/810,710 Restriction/Election Requirement dated Jan. 6, 2021. [cited by applicant]
U.S. Appl. No. 16/810,710 Office Action dated May 12, 2021. [cited by applicant]
U.S. Appl. No. 16/810,710 Office Action dated Mar. 30, 2022. [cited by applicant]
U.S. Appl. No. 17/899,157 Restriction/Election Requirement dated Oct. 30, 2023. [cited by applicant]
U.S. Appl. No. 17/899,157 Office Action dated Apr. 10, 2024. [cited by applicant]
Vyavahare et al., “Analysis of Structural Rearrangements of Poly(lactic acid) in the Presence of Water”, Journal Physical Chemistry B, vol. 118, No. 15, pp. 4185-4193 (2014). [cited by applicant]
Wang et al., “Characterization of the initial burst release of a model peptide from poly(D,L-lactide-co-glycolide) microspheres”, J. Controlled Release, vol. 82, pp. 289-307 (2002). [cited by applicant]
Xu et al., “Scalable method to produce biodegradable nanoparticles that rapidly penetrate human mucus”, Journal of Controlled Release, vol. 170, pp. 279-286 (2013). [cited by applicant]
Yu et al., “Nanotechnology for Protein Delivery: Overview and Perspectives”, J. Controlled Release, vol. 240, pp. 24-37 (32 pages) (Oct. 28, 2016). [cited by applicant]
Zandonella, “Bob Prud'homme - Flash NanoPrecipitation” http://research.princeton.edu/news/features/a/index.XML? id=6234, accessed Mar. 9, 2018, originally published Dec. 9, 2011, pp. 1-2. [cited by applicant]
Zhang et al., “Development of Nanoparticles for Antimicrobial Drug Delivery”, Current Medicinal Chemistry, vol. 17, No. 5, pp. 585-594 (2010). [cited by applicant]
Zhang et al., “Amphiphilic cylindrical brushes with poly(acrylic acid) core and poly(n-butyl acrylate) shell and narrow length distribution”, Polymer, vol. 44, No. 5, pp. 1449-1458 (2003). [cited by applicant]
Zhu et al., “Preparation and characterization of hCG-loaded polylactide or poly(lactide-co-glycolide) microspheres using a modified water-in-oil-in-water (w/o/w) emulsion solvent evaporation technique”, J. Microencapsul… [cited by applicant]
Bilati et al., “Nanoprecipitation Versus Emulsion-based Techniques for the Encapsulation of Proteins Into Biodegradable Nanoparticles and Process-related Stability Issues”, AAPS PharmSciTech, vol. 6, No. 4, Article 74, … [cited by applicant]
Hadinoto et al., “Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: A review”. European Journal of Pharmaceutics & Biopharmaceutics, vol. 85, No. 3, part A, pp. 427-443 (2013). [cited by applicant]
Kauffman et al., “Materials for non-viral intracellular delivery of messenger RNA therapeutics”, J. Controlled Release, vol. 240, pp. 227-234 (2016). [cited by applicant]
Mueller et al., “Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art”, European Journal of Pharmaceutics & Biopharmaceutics, vol. 50, No. 1, pp. 161-177 (2000). [cited by applicant]
Muheem et al., “A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives”, Saudi Pharmaceutical Journal, vol. 24, No. 4, pp. 413-428 (2016). [cited by applicant]
O'Reilly et al., “Cross-linked block copolymer micelles: functional nanostructures of great potential and versatility”, Chemical Society Reviews, vol. 35, pp. 1068-1083 (2006). [cited by applicant]
Okuyama et al., “Preparation of functional nanostructured particles by spray drying”, Advanced Powder Technol., vol. 17, No. 6, pp. 587-611 (2006). [cited by applicant]
Overbeek et al., “Phase separation in polyelectrolyte solutions. Theory of complex coacervation”, Journal of Cellular Physiology, vol. 49, No. S1, pp. 7-26 (1957). [cited by applicant]
Owens et al., “Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles”, International Journal of Pharmaceutics, vol. 307, No. 1, pp. 93-102 (2006). [cited by applicant]
Pagels et al., “Inverse Flash NanoPrecipitation for Biologics Encapsulation: Nanoparticle Formation and lonic Stabilization in Organic Solvents”, ACS Publications, vol. 1271, pp. 249-274 (2017). [cited by applicant]
Pagels et al., “Polymeric nanoparticles and microparticles for the delivery of peptides, biologics, and soluble therapeutics”, Journal of Controlled Release, vol. 219, pp. 519-535 & Supplemental Information (2015). [cited by applicant]
Patel et al., “A novel approach for antibody nanocarriers development through hydrophobic ion-pairing complexation”, Journal of Microencapsulation, vol. 31, No. 6, pp. 542-550 (2014). [cited by applicant]
Patil et al., “Retention of trypsin activity in spermine alginate microcapsules”, Journal of Microencapsulation, vol. 14, No. 4, pp. 469-474 (1997). [cited by applicant]
Pattni et al., “New Developments in Liposomal Drug Delivery”, Chemical Reviews, vol. 115, No. 19, p. 10938-10966 (2015). [cited by applicant]
Peters et al., “Biotech Products in Big Pharma Clinical Pipelines Have Grown Dramatically According to the Tufts Center for the Study of Drug Development”, Nov. 14, 2013, https://www.biospace.com/ ... a-clinical-pipelin… [cited by applicant]
Pham et al., “Micellar Solutions of Associative Triblock Copolymers: Entropic Attraction and Gas-Liquid Transition”, Macromolecules, vol. 32, No. 9, pp. 2996-3005 (1999). [cited by applicant]
Pinkerton et al., “Formation of Stable Nanocarriers by in Situ lon Pairing during Block-Copolymer-Directed Rapid Precipitation”, Molecular Pharmaceutics, vol. 10, No. 1, pp. 319-328 (2013). [cited by applicant]
Pitt, “The controlled parenteral delivery of polypeptides and proteins”, International Journal of Pharmaceutics, vol. 59, pp. 173-196 (1990). [cited by applicant]
Pustulka et al., “Flash Nanoprecipitation: Particle Structure and Stability”, Molecular Pharmaceutics, vol. 10, pp. 4367-4377 (2013). [cited by applicant]
Qi et al., “Determination of the Bioavailability of Biotin Conjugated onto Shell Cross-Linked (SCK) Nanoparticles”, Journal American Chemical Society, vol. 126, pp. 6599-6607 (2004). [cited by applicant]
Reinhold et al., “Self-healing Microencapsulation of Biomacromolecules without Organic Solvents”, Angew. Chem. Int. Ed. Engl., vol. 51, No. 43, pp. 10800-10803 (9 pages) (Oct. 22, 2012). [cited by applicant]
Reinhold et al., “Self-Healing Microencapsulalion of Biomacromolecules without Organic Solvents”, Angewandte Chemie, vol. 124, Issue 43, p. 10958-10961 (6 pages) (Oct. 2012). [cited by applicant]
Riess et al. “Emulsifying Properties of Block Copolymers. Oil-Water Emulsions and Microemulsions”, Polym. Eng. Sci., vol. 17, No. 8, pp. 634-638 (1977). [cited by applicant]
Rädler et al., “Structure of DNA-Cationic Liposome Complexes: DNA Intercalation in Multilamellar Membranes in Distinct Interhelical Packing Regimes”, Science, vol. 275, No. 5301, pp. 810-814 (Feb. 7, 1997), DOI: 10.1126… [cited by applicant]
Saad, W.S. & Prud'homme, R.K., “Principles of nanoparticle formation by flash nanoprecipitation”, Nano Today, vol. 11, No. 2, pp. 212-227 (2016). [cited by applicant]
Sahoo et al., “Characterization of Porous PLGA/PLA Microparticles as a Scaffold for Three Dimensional Growth of Breast Cancer Cells”, Biomacromolecules, vol. 6, pp. 1132-1139 (2005). [cited by applicant]
Salentinig et al., “Self-Assembled Structures and pKa Value of Oleic Acid in Systems of Biological Relevance”, Langmuir, vol. 26, No. 14, pp. 11670-11679 (2010). DOI: 10.1021/1a101012a. [cited by applicant]
Sato et al., “Therapeutic peptides: technological advances driving peptides into development”, Current Opinion in Biotechnology, vol. 17, pp. 638-642 (2006). [cited by applicant]
Savjani, K.T. et al., “Drug Solubility: Importance and Enhancement Techniques”, ISRN Pharmaceutics, vol. 2012, Article ID 195727, pp. 1-10 (2012). [cited by applicant]
Schwendeman et al., “Injectable controlled release depots for large molecules”, Journal of Controlled Release, vol. 190, pp. 240-253 (37 pages) (Sep. 28, 2014). [cited by applicant]
Serajuddin, “Salt formation to improve drug solubility”, Advanced Drug Delivery Reviews, vol. 59, No. 7, pp. 603-616 (2007). [cited by applicant]
Shah et al., Poly(glycolic acid-co-DL-lactic acid): diffusion or degradation controlled drug delivery?, Journal of Controlled Release, vol. 18, pp. 261-270 (1992). [cited by applicant]
Sheela, D.L et al., “Lauric acid induce cell death in colon cancer cells mediated by the epidermal growth factor receptor downregulation: An in silico and in vitro study”, Human & Experimental Toxicology, (Epub. Apr. 3,… [cited by applicant]
Sohn et al., “Polymer prodrug approaches applied to paclilaxel”, Polymer Chemistry, vol. 1, No. 6, pp. 778-792 (2010). [cited by applicant]
Solaro et al., “Targeted Delivery of Protein Drugs by Nanocarriers”, Materials, vol. 3, No. 3, pp. 1928-1980 (2010). [cited by applicant]
Song et al., “A novel in situ hydrophobic ion pairing (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system”, Journal of Controlled Release, vol. 229, pp. 106-119 (2016). [cited by applicant]
Sosa et al., “Soft Multifaced and Patchy Colloids by Constrained vol. Self-Assembly”, Macromolecules, vol. 49, pp. 3580-3585 (2016). [cited by applicant]
Steichen et al., “A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics”, European J. Pharmaceutical Sciences, vol. 48, pp. 416-427 (2013). [cited by applicant]
Talelli et al., “Core-crosslinked polymeric micelles: Principles, preparation, biomedical applications and clinical translation”, Nano Today, vol. 10, pp. 93-117 (2015). [cited by applicant]
Tang et al., “An innovative method for preparation of hydrophobic ion-pairing colistin entrapped poly(lactic acid) nanoparticles: Loading and release mechanism study”, European J. Pharmaceutical Sciences, vol. 102, pp. … [cited by applicant]
Turro et al., “Spectroscopic Probe Analysis of Protein-Surfactant Interactions: The BSA/SDS System”, Langmuir, vol. 11, No. 7, pp. 2525-2533 (1995). [cited by applicant]
U.S. Appl. No. 15/321,588 Notice of Allowance & Notice of Allowability dated Oct. 24, 2018. [cited by applicant]
U.S. Appl. No. 15/321,588 Office Action dated Apr. 10, 2018. [cited by applicant]
U.S. Appl. No. 15/321,588 Restriction/Election Requirement dated Dec. 1, 2017. [cited by applicant]
U.S. Appl. No. 15/321,588, filed Oct. 24, 2018 dated Summary of Examiner Interview of Oct. 9, 2018. [cited by applicant]
U.S. Appl. No. 16/064,935 Notice of Allowability dated Aug. 2, 2021. [cited by applicant]
U.S. Appl. No. 16/064,935 Notice of Allowability dated Jun. 21, 2021. [cited by applicant]
U.S. Appl. No. 16/064,935 Notice of Allowance & Notice of Allowability dated Oct. 21, 2020. [cited by applicant]
U.S. Appl. No. 16/064,935 Notice of Allowance & Notice of Allowability dated Apr. 28, 2021. [cited by applicant]
U.S. Appl. No. 16/064,935 Notice of Allowance & Notice of Allowability dated May 6, 2020. [cited by applicant]
U.S. Appl. No. 16/064,935 Restriction/Election Requirement dated Jan. 13, 2020. [cited by applicant]
U.S. Appl. No. 16/253,850 Restriction/Election Requirement dated Apr. 7, 2020. [cited by applicant]
U.S. Appl. No. 16/253,850 Office Action dated Sep. 8, 2020. [cited by applicant]
Aggarwal et al., “What's fueling the biotech engine - 2012 to 2013”, Nat. Biotechnol., vol. 32, No. 1, pp. 32-39, Jan. 2014. [cited by applicant]
Ansell et al., “Modulating the Therapeutic Activity of Nanoparticle Delivered Paclitaxel by Manipulating the Hydrophobicity of Prodrug Conjugates,” Journal of Medicinal Chemistry, vol. 51, No. 11, pp. 3288-3296 (2008). [cited by applicant]
Anton et al., “Aqueous-Core Lipid Nanocapsules for Encapsulating Fragile Hydrophilic and/or Lipophilic Molecules”, Langmuir, vol. 25, No. 19, pp. 11413-11419 (2009). [cited by applicant]
Antonietti et al., “Polyelectrolyte-Surfactant Complexes: A New Type of Solid, Mesomorphous Material”, Macromolecules, vol. 27, No. 21, pp. 6007-6011 (1994). [cited by applicant]
Antonov et al., “Entering and Exiting the Protein - Polyelectrolyte Coacervate Phase via Nonmonotonic Salt Dependence of Critical Conditions”, Biomacromolecules, vol. 11, No. 1, pp. 51-59 (2010). [cited by applicant]
Arshady, “Preparation of biodegradable microspheres and microcapsules: 2. Polyactides and related polyesters”, Journal of Controlled Release, vol. 17, pp. 1-22 (1991). [cited by applicant]
Babu, N.J. & Nangia, A., “Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals”, Crystal Growth & Design, vol. 11, pp. 2662-2679 (2011). [cited by applicant]
Bailly, N. et al. “Poly(N-vinylpyrrolidone)-block-poly(vinyl acetate) as a Drug Delivery Vehicle for Hydrophobic Drugs”, Biomacromolecules, vol. 13, pp. 4109-4117 (2012). [cited by applicant]
Basf, Luviscol VA Grades Technical Information, Jun. 2012, pp. 1-14. [cited by applicant]
Bilati et al., “Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles”, European J. Pharmaceutical Sciences, vol. 24, pp. 67-75 (2005). [cited by applicant]
Bontha et al., “Polymer micelles with cross-linked ionic cores for delivery of anticancer drugs”, Journal of Controlled Release, vol. 114, pp. 163-174 (2006). [cited by applicant]
Bronich et al., “Polymer Micelle with Cross-Linked lonic Core”, J. Am. Chem Soc., vol. 127, pp. 8236-8237 (2005). [cited by applicant]
Bronich et al., “Soluble Complexes from Poly(ethylene oxide)-block-polymethacrylate Anions and N-Alkylpyridinium Cations”, Macromolecules, vol. 30, pp. 3519-3525 (1997). [cited by applicant]
Bruno et al., Basics and recent advances in peptide and protein drug delivery, Therapeutic Delivery, vol. 4, No. 11, pp. 1443-1467 (45 pages) (2013). [cited by applicant]
Colombani et al., “Structure of Micelles of Poly(n-butyl acrylate)-block-poly(acrylic acid) Diblock Copolymers in Aqueous Solution,” Macromolecules, vol. 40, pp. 4351-4362 (2007). [cited by applicant]
Colombani et al., “Synthesis of Poly(n-butyl acrylate)-block-poly(acrylic acid) Diblock Copolymers by ATRP and Their Micellization in Water,” Macromolecules, vol. 40, pp. 4338-4350 (2007). [cited by applicant]
“The Complete Guide to Enteric Coating”, https://astenzymes.com/the-complete-guide-to-enteric-coating/, pp. 1-11, accessed Aug. 11, 2020. [cited by applicant]
Crater et al., “Barrier Properties of Gastrointestinal Mucus to Nanoparticle Transport,” Macromolecular Bioscience, vol. 10, No. 12, pp. 1473-1483 (2010). [cited by applicant]
Cu et al., “Drug delivery: Stealth particles give mucus the slip”, Nature Materials, vol. 8, No. 1, pp. 11-13 (Jan. 2009). [cited by applicant]
D'Addio & Prud'Homme, “Controlling drug nanoparticle formation by rapid precipitation”, Advanced Drug Delivery Reviews, vol. 63, No. 6, pp. 417-426 (2011). [cited by applicant]
Davies et al., “Recent advances in the management of cystic fibrosis”, Archives of Disease in Childhood, vol. 99, No. 11, pp. 1033-1036 (2014). [cited by applicant]
Deng et al., “Janus Nanoparticles of Block Copolymers by Emulsion Solvent Evaporation Induced Assembly”, Macromolecules, vol. 49, pp. 1362-1368 (2016). [cited by applicant]
Eghbali et al., “Rheology and Phase Behavior of Poly(n-butyl acrylate)-block-poly(acrylic acid) in Aqueous Solution”, Langmuir, vol. 22, pp. 4766-4776 (2006). [cited by applicant]
Ensign et al., “Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers,” Advanced Drug Delivery Reviews, vol. 64, No. 6, pp. 557-570 (2012). [cited by applicant]
Erre et al., “Chromium(III) Acetate, Chromium(III) Acetate Hydroxide, or mu3-Oxo-esakis-(mu2-acetato-O,O')- triaqua-trichromium(III) Acetate?”, Journal of Chemical Education, vol. 74, No. 4, pp. 432-435 (Apr. 1997). [cited by applicant]
Extended European Search Report (EESR) dated Jan. 8, 2018 in European Application No. 15811879.4. [cited by applicant]
“Enteric Coating—The Enteric Coating Process”, https://www.xtend-life.com/pages/enteric-coating, pp. 1-6, accessed Aug. 12, 2020. [cited by applicant]
Etchenausia, L. et al., “RAFT/MADIX emulsion copolymerization of vinyl acetate and N-vinylcaprolactam: towards waterborne physically crosslinked thermoresponsive particles”, Polymer Chemistry, Doi: 10.1039/C7PY00221A, p… [cited by applicant]
Foerster et al., “Amphiphilic Block Copolymers in Structure-Controlled Nanomaterial Hybrids”, Advanced Materials, vol. 10, No. 3, pp. 195-217 (1998). [cited by applicant]
Galindo-Rodriguez et al., “Polymeric Nanoparticles for Oral Delivery of Drugs and Vaccines: A Critical Evaluation of In Vivo Studies”, Critical Reviews in Therapeutic Drug Carrier Systems, vol. 22, No. 5, pp. 419-463 (2… [cited by applicant]
Gao et al., “Core Cross-Linked Reverse Micelles from Star-Shaped Polymers”, Chemistry of Materials, vol. 20, pp. 3063-3067 (2008). [cited by applicant]
Gaudana et al., “Design and evaluation of a novel nanoparticulate-based formulation encapsulating a HIP complex of lysozyme”, Pharmaceutical Development & Technology, vol. 18, No. 3, pp. 752-759 (2013). [cited by applicant]
Gindy et al., “Mechanism of Macromolecular Structure Evolution in Self-Assembled Lipid Nanoparticles for siRNA Delivery”, Langmuir, vol. 30, No. 16, pp. 4613-4622 (2014). [cited by applicant]
Google Scholar NPL search string - downloaded Apr. 29, 2020, 1 page. [cited by applicant]
Gregory et al., “Adsorption and flocculation by polymers and polymer mixtures”, Advances in Colloid & Interface Science, vol. 169, No. 1, pp. 1-12 (2011). [cited by applicant]
Groeschel et al., “Guided hierarchical co-assembly of soft patchy nanoparticles”, Nature, vol. 503, pp. 247-251 (5 p. & 11 p. Methods, Extended Data Figures 1-9, & Extended Data Table 1) (Nov. 14, 2013). [cited by applicant]
Guo, Q. et al., “Binding of dihydromyricetin and its metal ion complexes with bovine serum albumin”, Biotechnology & Biotechnological Equipment, vol. 28, No. 2, pp. 333-341 (2014). [cited by applicant]
Guo, Q. et al., “Biosynthesis of gold nanoparticles using a kind of flavanol: Dihydromyricetin”, Colloids & Surfaces A: Physicochem. & Engineering Aspects, vol. 441, pp. 127-132 (2014). [cited by applicant]
Guo, Q. et al., “Synthesis of dihydromyricetin-manganese (II) complex and interaction with Dna”, J. Molecular Structure, vol. 1027, pp. 64-69 (2012). [cited by applicant]
Holland et al., “Polymers for Biodegradable Medical Devices, 1. The Potential of Polyesters As Controlled by Macromolecular Release Systems”, Journal of Controlled Release, vol. 4, pp. 155-180 (1986). [cited by applicant]
Horigome et al., “Long-Time Relaxation of Suspensions Flocculated by Associating Polymers”, Langmuir, vol. 18, No. 5, pp. 1968-1973 (2002). [cited by applicant]
HØiby, “Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis”, BMC Medicine, vol. 9, No. 32, pp. 1-7 (2011). [cited by applicant]
Ilton et al., “Direct Measurement of the Critical Pore Size in a Model Membrane”, Physical Review Letters, 117, Issue 25, p. 257801-1 through 257801-5 (Dec. 16, 2016). [cited by applicant]
Immordino et al., “Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential”, International Journal of Nanomedicine, vol. 1, No. 3, pp. 297-315 (2006). [cited by applicant]
International Patent Application PCT/US2015/017590 International Search Report and Written Opinion dated Jul. 16, 2015. [cited by applicant]
International Patent Application PCT/US2015/036060 International Search Report and Written Opinion dated Sep. 18, 2015. [cited by applicant]
International Patent Application PCT/US2016/068145 International Search Report and Written Opinion dated Mar. 23, 2017. [cited by applicant]
International Patent Application PCT/US2017/054779 International Search Report and Written Opinion dated Jan. 26, 2018. [cited by applicant]
International Patent Application PCT/US2018/050714 International Preliminary Report on Patentability mailed Mar. 26, 2020 (issued Mar. 17, 2020). [cited by applicant]
International Patent Application PCT/US2018/049580 International Search Report and Written Opinion dated Jan. 15, 2019. [cited by applicant]
Xu et al., “Influence of experimental parameters and the copolymer structure on the size control of nanospheres in double emulsion method”, J. Polymer Research, vol. 18, pp. 131-137 (2011). [cited by applicant]
U.S. Appl. No. 18/083,458 Restriction/Election Requirement dated Aug. 1, 2024. [cited by applicant]
Cited By (1)
US 12,605,344